#varegacestat
Latest news and interesting information about varegacestat.
Immunome presents phase 3 trial results for desmoid tumor drug
Immunome announces phase 3 results for varegacestat in desmoid tumors: 84% reduction in progression risk, 56% objective response rate.
...
